Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy

This study has suspended participant recruitment.
(FDA placed the protocol on clinical hold while new data are evaluated. Enrolled subjects are not taking HT-100. Clinic visits are continuing per protocol.)
Information provided by (Responsible Party):
Halo Therapeutics, LLC Identifier:
First received: May 2, 2013
Last updated: December 23, 2013
Last verified: December 2013
No Study Results Posted on for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: June 2014
  Estimated Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)